RxDoctor Payments Data

Jason Jacobs, MD

Ophthalmology · Denver, CONPI 1750379954

Payments from drug & device makers

$2,603in general payments, 2019–2025

Across 102 payments — averaging $25.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$821
  • AbbVie$356
  • Bausch & Lomb Americas Inc.$312
  • Johnson & Johnson Surgical Vision, Inc.$130
  • Novartis$115
  • Mallinckrodt Hospital Products Inc.$114
  • plus $756 from 18 others

What the payments were for

  • Food & beverage$2,49296%
  • Gifts$191%
  • Entertainment$924%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,603 in reported general payments places this provider in the 65th percentile of 262 ophthalmology providers in Colorado.

See all ophthalmology providers in Colorado

Medicare billing

Part B allowed, 2024
$369,821
Medicare patients
1,126
Services billed
2,764

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine136$128,033
Cyclosporine53$24,833
XiidraLifitegrast25$21,433
MieboPerfluorohexyloctane/Pf26$19,176
VyzultaLatanoprostene Bunod43$14,488
VevyeCyclosporine15$11,201
LumiganBimatoprost16$9,093
AlrexLoteprednol Etabonate11$6,257
Latanoprost368$4,102
Travoprost14$3,725
SimbrinzaBrinzolamide/Brimonidine Tart12$3,188
CombiganBrimonidine Tartrate/Timolol16$3,184
Fluorometholone30$2,997
Prednisolone Acetate23$1,668
Timolol Maleate47$1,278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$356$140,310168 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$312$55,09794 claims
Harrow Eye, LLCVevye$18$11,20115 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCAlrex$24$6,25711 claims
AlconSimbrinza$821$3,18812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 262 ophthalmology providers in Colorado.

Other ophthalmology in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →